Nektar Therapeutics
NKTR News Today: Stay Updated with the Latest Nektar Therapeutics News in Real Time
Find NKTR news now at Meyka AI. Stay informed with the latest Nektar Therapeutics stocks updates, including price news, market analysis, and expert insights.
MMTX.SW stock surges 26% on high volume trading in April 2026
MMTX.SW stock jumps 26% with 659K shares traded. MindMaze Therapeutics gains momentum on SIX exchange.
GILD Earnings Preview: April 22, 2026 – What to Expect
Gilead Sciences earnings preview for April 22, 2026. Analyst expectations, historical performance, and key metrics to watch.
NKTR Maintained at Buy by H.C. Wainwright, April 2026
H.C. Wainwright maintains NKTR at Buy rating with price target raised to $185 from $165 on April 20, 2026.
PHRM.CN Stock Surges 46.67% on Earnings Catalyst, Apr 20
PHRM.CN stock jumps 46.67% to C$0.11 on earnings catalyst. PharmaTher Holdings reports strong momentum ahead of April 21 earnings announcement.
SMMT Upgraded to Buy by UBS: Initial Coverage April 2026
UBS initiates coverage of Summit Therapeutics (SMMT) with Buy rating on April 17, 2026. Stock trades at $25.15.
UTHR Insider Trades: Directors and CFO Sell $2.5M in Stock April 2026
United Therapeutics insiders sold $2.5M in stock on April 16-17, 2026. CEO Rothblatt acquired shares while director and CFO disposed positions.
PLRX Insider Buying: 4 Executives Acquire Stock Options April 17, 2026
Pliant Therapeutics insiders acquire 837,000 stock options worth $1.1M on April 17. CEO, CFO, COO, and CHRO all buy in coordinated action.
ALNA Stock Surges 3.16% in Pre-Market Trading on Apr 17
ALNA stock rises 3.16% to $0.075 in pre-market session with 252M shares traded. Allena Pharmaceuticals faces headwinds.
SRPT Maintained at Sell by H.C. Wainwright, April 2026
H.C. Wainwright maintains Sell rating on SRPT, citing Roche decision impact on U.S. market prospects for Sarepta Therapeutics.